Director of Research
Australia and New Zealand Breast Cancer Trials Group
Professor of Surgical Oncology
University of Newcastle
On behalf of the Australian New Zealand Breast Cancer Trials Group
Co-Investigator: Jack Cuzick, PhD, Queen Mary, University of London, Cancer Research UK, London, United Kingdom
This project, involving the collaboration of multiple medical centers around the world, aims to identify biomarkers of breast cancer risk by studying the relationship between biomarkers and outcomes in large randomized controlled trials. The BCRF grant in 2013-2014 will continue to assist the Australia and New Zealand Breast Cancer Trials Group in developing the High Risk Breast Bio-bank (HRBB). Collection of tissue and mammograms from women participating in two multinational trials: 1) IBIS II, a primary prevention trial and a ductal carcinoma in situ (DCIS) trial for women at increased risk of breast cancer recurrence, and 2) LATER, a trial for prevention of later recurrences after a prior diagnosis of hormone sensitive breast cancer. Accrual to IBIS II is complete but follow-up tissue (tumor and bloods) will be collected from participants. Samples are also being sought from breast cancers occurring in the last three years from IBIS I women (IBIS I commenced in 1996) to further complement the bio data already collected. Transfers of all tissues to the UK continue for analysis. IT specialists continue to research and analyze existing tissue bank databases to ensure user-friendly access worldwide.
Drs. Forbes and Cuzick report that development of the High Risk Breast Bio-bank (HRBB) continues. A framework detailing how the tissue management protocols (from collection, recording, allocating to research projects, tracking and recording results) is being developed. A Materials Transfer Agreement has been developed and a first request for samples has been received. A committee has been established in order to assess requests for tissue to ensure that the tissue use is maximized. A pilot study to assess the feasibility of recruiting to IBIS III will commence in 2014 and the collection of blood serum, pathology and mammograms will be an integral part. These samples from IBIS III will be recorded in the HRBB together with the IBIS I, IBIS II DCIS and LATER samples. The first results from IBIS II were presented at the 2013 San Antonio Breast Cancer Symposium and were published at that time in The Lancet. Anastrozole was shown to be effective in significantly lowering the risk of breast cancer in postmenopausal women at increased risk for breast cancer.